C4 Imaging has announced the signing of a loading services agreement for it's first product, the Sirius MRI Marker, with AnazaoHealth.
The novel positive-signal, MRI marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant magnetic resonance imaging procedure.
C4 Imaging will partner with AnazaoHealth, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.
C4 Imaging president and CEO Andrew Bright noted that AnazaoHealth has a long-standing reputation for quality and service to the prescription-loaded prostate brachytherapy market.
"We are delighted to partner with them, allowing broad access to our Sirius™ MRI Marker for prostate brachytherapy physicians and seed vendors alike," Bright added.
AnazaoHealth president and COO Chris A Arnette noted that while C4 Imaging is a new entrant into the US prostate brachytherapy market the company’s management team is highly experienced in this area.
"We are excited to partner with them as they introduce the Sirius™ MRI Marker. Sirius™ has the potential to revolutionize prostate brachytherapy; with improved MRI based post-implant imaging leading to further increases in the quality of this highly-effective and cost-effective treatment option," Arnette added.